[
  {
    "ts": null,
    "headline": "Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best affordable biotech stocks to invest in now. In a report released on September 15, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) and set a price target of $104.00. Incyte Corporation (NASDAQ:INCY) reported total revenues of $1.216 billion in its fiscal […]",
    "url": "https://finnhub.io/api/news?id=16537ab82d3a07897da3f2bcfcf6ff2308b44bffd540a5026c80a3b23767394c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758137227,
      "headline": "Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT",
      "id": 136791865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best affordable biotech stocks to invest in now. In a report released on September 15, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) and set a price target of $104.00. Incyte Corporation (NASDAQ:INCY) reported total revenues of $1.216 billion in its fiscal […]",
      "url": "https://finnhub.io/api/news?id=16537ab82d3a07897da3f2bcfcf6ff2308b44bffd540a5026c80a3b23767394c"
    }
  },
  {
    "ts": null,
    "headline": "INCY Announces New Late-Stage Data on Skin Disease Drug",
    "summary": "Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.",
    "url": "https://finnhub.io/api/news?id=f009b0f61c0a126c5a781067b8c5feaebb38c78132f9580866b8ae69988d5dfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758119880,
      "headline": "INCY Announces New Late-Stage Data on Skin Disease Drug",
      "id": 136790065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.",
      "url": "https://finnhub.io/api/news?id=f009b0f61c0a126c5a781067b8c5feaebb38c78132f9580866b8ae69988d5dfc"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
    "summary": "WILMINGTON, Del., September 17, 2025--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
    "url": "https://finnhub.io/api/news?id=765f4b1d8188a9283a649ec16a1a10acec8b5ffa23bc72a881112d7e80b2ccd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758088800,
      "headline": "Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
      "id": 136787854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., September 17, 2025--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025",
      "url": "https://finnhub.io/api/news?id=765f4b1d8188a9283a649ec16a1a10acec8b5ffa23bc72a881112d7e80b2ccd0"
    }
  }
]